KTR established Korea’s first Animal Alternative Testing Center and has built related facilities in the biopharmaceutical sector to provide an innovative research environment.
Currently, toxicity evaluations required in the drug development process are conducted through alternative testing methods, with six OECD TG experiments already implemented. In addition, a variety of alternative tests are systematically operated under GLP certification.
Lambda Biologics and KTR possess collaborative infrastructure across all stages of drug development:
R&D → Preclinical (GLP) → Clinical (GCP) → Manufacturing (GMP)
Notably, for drugs that are challenging to evaluate using conventional platforms (e.g., immune-oncology agents, anaerobic bacteria evaluation), organoid technology is utilized to overcome these limitations. This advanced research is carried out with greater precision and efficiency through collaboration with LambdaBiologics.
Especially for medications where efficacy is difficult to assess using traditional platforms, such as immune-oncology agents or anaerobic bacteria evaluation, supplementary assessments using organoids are conducted in partnership with LambdaBiologics.
